Ketamine Inhibits Lung Fluid Clearance through Reducing Alveolar Sodium Transport

Table 1

Clinical characteristics of patients.

	Control (𝑛=6)	Amiloride (𝑛=5)	Ketamine (𝑛=5)	Keta+am (𝑛=5)
Age (year)	60.0±8.6	64.8±11.4	60.0±8.1	50.4±3.9
Male (%)	50	40	60	80
PaO2 (mmHg)	87.4±4.5	86.9±6.8	83.7±8.3	90.2±6.0
VC (L)	3.3±0.5	3.1±0.9	3.2±0.9	4.2±0.7
FEV1.0 actual value (L)	2.4±0.4	2.4±0.9	2.7±0.8	3.2±0.5
FEV1.0 actual/predicted (%)	96.3±21.6	108.2±10.7	96.3±17.4	97.3±10.4
FVC actual value (L)	3.2±0.4	3.1±0.9	3.2±0.9	3.8±0.6
FVC actual/predicted (%)	103.6±27.8	113.0±24.1	92.5±9.6	87.5±4.8
FEV1.0/FVC (%)	74.6±10.3	77.9±7.9	84.0±10.0	83.9±3.8

VC: vital capacity; FEV_1.0: forced expiratory volume in 1.0 s; FVC: forced vital capacity. One-way ANOVA.